Agenus shows unprecedented activity for botensilimab/balstilimab combination in microsatellite stable colorectal cancer at esmo world gi congress

Lexington, mass., june 29, 2022 (globe newswire) -- agenus (nasdaq: agen), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced expanded data from the phase 1b study of botensilimab (fc-enhanced anti-ctla-4) and balstilimab (anti-pd-1) in patients with microsatellite stable colorectal cancer (mss crc). the data demonstrate that the combination offers strong durability and superior efficacy than what has been reported in separate trials for standard of care and other investigational therapies in 2l+ mss crc.
AGEN Ratings Summary
AGEN Quant Ranking